EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic products to combat public health threats and infectious diseases, thereby building a strong foundation of technical expertise in working with complex molecules and delivering them to the market.

Drawing on this fundamental experience, its CDMO business has supported the development and manufacturing of over 40 commercial and more than 100 clinical biologic programs for their biopharma partners.

Drug Development & Delivery recently interviewed Bill Hartzel, who joined the company in March 2022 as Senior Vice President and Head of CDMO Business, to discuss the company’s plans for current and future CDMO operations and client partnership opportunities.